Year |
Citation |
Score |
2022 |
Athans S, Krishnan N, Ramakrishnan S, Cortes Gomez E, Lage-Vickers S, Rak M, Kazmierczak Z, Ohm J, Attwood K, Wang J, Woloszynska A. STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. Cancer Research Communications. 2: 1129-1143. PMID 36275363 DOI: 10.1158/2767-9764.crc-22-0155 |
0.369 |
|
2021 |
Mastri M, Ramakrishnan S, Shah SD, Karasik E, Gillard BM, Moser MT, Farmer BK, Azabdaftari G, Chatta GS, Woloszynska A, Eng KH, Foster BA, Huss WJ. Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment. American Journal of Clinical and Experimental Urology. 9: 416-434. PMID 34993263 |
0.334 |
|
2020 |
Krishnan N, Aquila L, Vickers SL, Ramakrishnan S, Atwood K, Hu Q, Cortes EG, Wang J, Woloszynska A. Abstract A22: STAG2, a novel genetic regulator of bladder cancer Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-A22 |
0.43 |
|
2020 |
Ramakrishnan S, Peng X, Gomez EC, Attwood K, Yan L, Wilton J, Azabdaftari G, Mohler J, Wang J, Woloszynska A. Abstract B087: Role of GATA-4-Androgen-AR axis in prostate cancer from African American men Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B087 |
0.301 |
|
2019 |
Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma. Molecular Cancer Therapeutics. PMID 31582532 DOI: 10.1158/1535-7163.Mct-18-1202 |
0.593 |
|
2019 |
Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693 |
0.584 |
|
2019 |
Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death and Differentiation. PMID 30692641 DOI: 10.1038/S41418-019-0278-9 |
0.458 |
|
2018 |
Ramakrishnan S, Peng X, Qi Q, Hu Q, Azabdaftari G, Pop E, Mohler J, Attwood K, Yan L, Wang J, Woloszynska-Read A. Abstract B72: DNA methylation and genetic alterations contribute to aggressive prostate cancer in African American men Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B72 |
0.362 |
|
2017 |
Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death & Disease. 8: 3217. PMID 29242529 DOI: 10.1038/S41419-017-0024-5 |
0.579 |
|
2016 |
Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Cortes Gomez E, Sun Y, Conroy J, Miles KM, Malathi K, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. PMID 27823983 DOI: 10.18632/Oncotarget.13062 |
0.533 |
|
2016 |
Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. Bmc Cancer. 16: 617. PMID 27506904 DOI: 10.1186/S12885-016-2604-7 |
0.568 |
|
2016 |
Mori H, Yao Y, Learman BS, Kurozumi K, Ishida J, Ramakrishnan SK, Overmyer KA, Xue X, Cawthorn WP, Reid MA, Taylor M, Ning X, Shah YM, MacDougald OA. Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion. Scientific Reports. 6: 21520. PMID 26861754 DOI: 10.1038/Srep21520 |
0.318 |
|
2015 |
Majumder K, Arora N, Modi S, Chugh R, Nomura A, Giri B, Dawra R, Ramakrishnan S, Banerjee S, Saluja A, Dudeja V. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 26582596 DOI: 10.1007/s11605-015-2985-y |
0.326 |
|
2015 |
Zhang H, Ramakrishnan SK, Triner D, Centofanti B, Maitra D, Győrffy B, Sebolt-Leopold JS, Dame MK, Varani J, Brenner DE, Fearon ER, Omary MB, Shah YM. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Science Signaling. 8: ra98. PMID 26443705 DOI: 10.1126/Scisignal.Aac5418 |
0.374 |
|
2015 |
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. PMID 26119935 DOI: 10.1038/Onc.2015.219 |
0.627 |
|
2015 |
Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 6: 3136-46. PMID 25605014 DOI: 10.18632/Oncotarget.3077 |
0.637 |
|
2015 |
Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular Cancer Therapeutics. 14: 513-22. PMID 25519701 DOI: 10.1158/1535-7163.Mct-14-0208 |
0.59 |
|
2015 |
Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular Cancer Therapeutics. 14: 101-10. PMID 25381264 DOI: 10.1158/1535-7163.Mct-14-0094 |
0.607 |
|
2015 |
Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research. 3: 136-48. PMID 25370534 DOI: 10.1158/2326-6066.Cir-14-0036 |
0.65 |
|
2015 |
Luo W, Ma Y, Baldino C, Caserta J, Ramakrishnan S, Roberto P, Johnson C, Trump D. Abstract 5056: PIM-1 kinase regulates vitamin D receptor signaling in human renal carcinoma cells Cancer Research. 75: 5056-5056. DOI: 10.1158/1538-7445.Am2015-5056 |
0.376 |
|
2015 |
Orillion A, Adelaiye-Ogala R, Shen L, Ciamporcero E, Ku SY, Ramakrishnan S, Elbanna M, Chintala S, Pili R. Abstract 4110: Inhibition of angiopoietin 1/2 and c-MET impairs metastatic potential in a patient derived xenograft of renal carcinoma Cancer Research. 75: 4110-4110. DOI: 10.1158/1538-7445.Am2015-4110 |
0.576 |
|
2015 |
Ku S, Ramakrishnan S, Ciamporcero E, Xu B, Azabdaftari G, Cheney R, Pili R. Abstract 2546: HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma Cancer Research. 75: 2546-2546. DOI: 10.1158/1538-7445.Am2015-2546 |
0.663 |
|
2015 |
Shen L, Orillion A, Adelaiye R, Ciamporcero E, Ramakrishnan S, Pili R. Abstract 2514: Activity of a novel Foxp3-tumor cell vaccine in a murine model of renal cell carcinoma Cancer Research. 75: 2514-2514. DOI: 10.1158/1538-7445.Am2015-2514 |
0.59 |
|
2015 |
Elbanna MF, Ciamporcero E, Ramakrishnan S, Adelaiye R, Shen L, Orillion A, Ku S, Chintala S, Pili R. Abstract 1462: Characterization of patient-derived bladder cancer xenografts: role of xCT in response to cisplatin Cancer Research. 75: 1462-1462. DOI: 10.1158/1538-7445.Am2015-1462 |
0.574 |
|
2014 |
Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Plos One. 9: e103680. PMID 25072314 DOI: 10.1371/Journal.Pone.0103680 |
0.623 |
|
2014 |
Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene. 33: 4961-5. PMID 24186201 DOI: 10.1038/Onc.2013.455 |
0.596 |
|
2014 |
Chintala S, Nguyen H, Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Pili R. Abstract 686: Regulation of intracellular sequestration of sunitinib by cystine transporter xCT in renal cancer Cancer Research. 74: 686-686. DOI: 10.1158/1538-7445.Am2014-686 |
0.614 |
|
2014 |
Ramakrishnan S, Ku S, Swetzig W, Conroy D, Shen L, Chintala S, Sotomayor P, Miles KM, Adelaiye R, Ciamporcero E, Orillion A, Ellis L, Das G, Pili R. Abstract 4061: Evidence for hdac6 and er-α association in a subset of clear cell renal cell carcinoma Cancer Research. 74: 4061-4061. DOI: 10.1158/1538-7445.Am2014-4061 |
0.61 |
|
2014 |
Ciamporcero ES, Shen H, Chintala S, Ramakrishnan S, Ku SY, Miles KM, Pizzimenti S, Johnson C, Zhang J, Barrera G, Pili R. Abstract 3754: Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder Cancer Research. 74: 3754-3754. DOI: 10.1158/1538-7445.Am2014-3754 |
0.634 |
|
2014 |
Adelaiye R, Miles KM, Ciamporcero E, Conroy D, Ramakrishnan S, Orillion A, Ku SY, Elbanna M, shen L, Chintala S, Pili R. Abstract 1375: Epigenetic changes associated with resistance to sunitinib in human clear cell renal cell carcinoma models Cancer Research. 74: 1375-1375. DOI: 10.1158/1538-7445.Am2014-1375 |
0.658 |
|
2014 |
Orillion A, Miles KM, Shen L, Adelaiye R, Ciamporcero E, Ramakrishnan S, Ku SY, Elbanna M, Chintala S, Pili R. Abstract 1013: Angiopoietin 1/2 inhibition impairs tumor growth in an orthotopic model of renal cell carcinoma Cancer Research. 74: 1013-1013. DOI: 10.1158/1538-7445.Am2014-1013 |
0.645 |
|
2013 |
Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 4: 2225-36. PMID 24163230 DOI: 10.18632/Oncotarget.1314 |
0.61 |
|
2013 |
Ramakrishnan S, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5: 453-62. PMID 23895657 DOI: 10.2217/Epi.13.40 |
0.575 |
|
2013 |
Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 333-40. PMID 23867515 DOI: 10.1097/Ppo.0B013E3182A09E07 |
0.596 |
|
2013 |
Ramakrishnan S, Sotomayor P, Ellis L, Chintala S, Pili R. Abstract 2987: VHL dependent and independent regulation of HDAC expression and activity in renal cell carcinomas. Cancer Research. 73: 2987-2987. DOI: 10.1158/1538-7445.Am2013-2987 |
0.661 |
|
2012 |
Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Plos One. 7: e30815. PMID 22303460 DOI: 10.1371/Journal.Pone.0030815 |
0.634 |
|
2012 |
Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate. 72: 587-91. PMID 21796655 DOI: 10.1002/Pros.21465 |
0.609 |
|
2012 |
Ellis L, Ramakrishnan S, Ku S, Pili R. Abstract C7: Targeting the androgen receptor with novel combination therapeutic strategies in metastatic/castrate-resistant prostate cancer Cancer Research. 72: C7-C7. DOI: 10.1158/1538-7445.Prca2012-C7 |
0.601 |
|
2012 |
Ramakrishnan S, Sotomayor P, Lehet K, Pili R. Abstract 5016: Epigenetics in renal cell carcinoma Cancer Research. 72: 5016-5016. DOI: 10.1158/1538-7445.Am2012-5016 |
0.649 |
|
2012 |
Ramakrishnan S, Pili R. Epigenetic targeting and histone deacetylase inhibition in RCC Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. 2147483647: 193-211. DOI: 10.1007/978-1-4614-2400-0_9 |
0.583 |
|
2011 |
Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. Plos One. 6: e27178. PMID 22087262 DOI: 10.1371/Journal.Pone.0027178 |
0.652 |
|
2011 |
Ellis L, Lehet K, Ramakrishnan S, Miles K, Wang D, Liu S, Atadja P, Carducci M, Pili R. 7054 POSTER Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in MicroRNA Expression European Journal of Cancer. 47: S501. DOI: 10.1016/S0959-8049(11)72005-6 |
0.478 |
|
Show low-probability matches. |